Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2
diabetes was demonstrated in the LEADER (ClinicalTrials. gov: NCT01179048) and …

Associations between body mass index (BMI) and the cardiovascular (CV) and kidney
efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in patients with type 2 …

It is unknown if the cardioprotective and renal effects of glucagon‐like peptide‐1 receptor
agonists are consistent across blood pressure (BP) categories in patients with type 2 …

Background: LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of CV
Outcome Results) results demonstrated cardiovascular benefits for patients with type 2 …

In the last years, due to new regulatory guidelines requiring a stringent documentation of
cardiovascular (CV) safety of novel drugs for type 2 diabetes, cardiovascular outcomes …

Background The once-daily glucagon-like peptide 1 (GLP-1) analogue, liraglutide has been
shown to reduce major adverse cardiovascular events (MACE) and progression of chronic …

Aim To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients
with type 2 diabetes (T2D) and peripheral artery disease (PAD). Materials and Methods …

Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide
on kidney outcomes in type 2 diabetes. Methods: Pooled (n= 12 637) and by-trial data from …

OBJECTIVE The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial (ClinicalTrials. gov reg. no. NCT01179048) demonstrated a …

Background: Liraglutide is a glucagon-like 1 (GLP-1) agonist approved for treatment of type
2 diabetes and obesity. Objective: To review the cardiovascular effects of liraglutide …